Biotricity, Inc. - Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)		3 Months Ended		6 Months Ended
		Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Income Statement
Revenue
Expenses:
General and administrative expenses	[1]	534,438	293,694	869,524	1,732,905
Research and development expenses	[2]	266,370	198,319	507,859	565,513
Total Operating Expenses		800,808	492,013	1,377,383	2,298,418
Accretion expense	[3]	120,531		194,103
Change in fair value of derivative liabilities	[4]	123,268		742,227
Net loss before income taxes		(1,044,607)	(492,013)	(2,313,713)	(2,298,418)
Income taxes
Net loss		(1,044,607)	(492,013)	(2,313,713)	(2,298,418)
Translation adjustment		(129,591)	193,585	(191,109)	59,655
Net loss and comprehensive loss		$ (1,174,198)	$ (298,428)	$ (2,054,822)	$ (2,238,763)
Loss per share, basic and diluted		$ (0.0418)	$ (0.0232)	$ (0.0925)	$ (0.1053)
Weighted average number of common shares outstanding		24,999,978	21,247,744	24,999,978	21,832,673

[1] See Notes 9 and 10

[2] See Note 11

[3] See Note 7

[4] See Note 8